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Coagulation factor X (FX) is a serine protease playing a pivotal role in the clotting 
process. It exerts its function by catalyzing thrombin formation, ultimately leading to 
the generation of fibrin from fibrinogen to produce a stable clot (Figure 1A).1 This 
mechanism prevents excessive blood loss after injury; however, it can also cause 
the generation of pathologic thrombi in blood vessels, blocking blood flow to a tissue 
and eventually resulting in ischemia and tissue death. An example is the acute 
coronary syndrome (ACS), the most severe complication of coronary artery disease 
(CAD). ACS commonly results from atherosclerotic plaque rupture, followed by 
platelet and coagulation cascade activation, which leads to a thrombus formation in 
the coronary arteries.2,3 Since activated FX (FXa) is central in the coagulation 
cascade, being involved in the initiation, amplification, and propagation phases of 
clot formation (Figure 1A), its specific inhibition was demonstrated to be effective in 
the prevention/treatment of life-threatening thrombi formation in arterial 
atherothrombotic diseases and venous thromboembolism.3,4 FXa inhibitors (i.e., 
rivaroxaban, apixaban, edoxaban) were proven to reduce the risk of stroke and 
systemic embolism in patients with nonvalvular atrial fibrillation, and to treat and/or 
prevent deep-venous thrombosis and pulmonary embolism. Rivaroxaban was shown 
to reduce the risk of major cardiovascular events in patients with a recent ACS when 
co-administered with antiplatelet therapies.5 Recently, the association between 
rivaroxaban and aspirin was proposed to improve cardiovascular outcomes even in 
patients with stable atherosclerotic vascular disease.6 Therefore, growing evidence 
emphasizes the role of FXa in the modulation of the residual cardiovascular risk in 
ischemic heart disease. 
Besides coagulation, FX is implicated in inflammation, tissue fibrosis, and vascular 
remodeling through the interaction with protease-activated receptors (PARs).7,8 
PARs belong to a family of 7-transmembrane, G protein-coupled receptors that are 
activated by different serine proteases by specific N-terminal cleavage. FXa 
activates PAR-1 and PAR-2, expressed in endothelial cells (ECs), dendritic cells, 
leukocytes, fibroblasts, and vascular smooth muscle cells (VSMCs). Recent findings 
suggested that FXa and its major receptor, PAR-2, play an important role in the 
pathophysiology of inflammatory diseases, including atherosclerosis (Figure 1B,C).9-
11
 In this frame, Hara and colleagues demonstrated that the administration of 
rivaroxaban reduces atherosclerotic plaque progression in ApoE-deficient mice by 
decreasing lipid deposition, macrophage accumulation, and MMP-9 expression 
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within plaques.10 This indicates that FXa inhibition may attenuate plaque 
progression/destabilization beyond the influence on coagulation pathway. 
Importantly, the inflammation response was also affected: after treatment, 
expression levels of TNF-α, Cox-2, iNOS, MCP-1, and IL-1β were significantly 
reduced in atherosclerotic plaques and macrophages.10 Consistently, FXa proteolytic 
activities were found significantly increased in early atherosclerotic lesions compared 
to lesions at a later stage, suggesting an important role for this protease also in the 
initial development of atherosclerosis.12 
Naturally occurring DNA variants affecting the expression/activity of drug protein 
targets can give insights in the therapeutic treatment directed against such gene 
products. Mutations lowering the expression of a drug-target gene are hence 
particularly interesting, because they may mimic the effect of pharmacological 
inhibition.13 According to this notion, variants disrupting the protein function of 2 
drug-target genes, PCSK9 and NPC1L1, were demonstrated to be associated with a 
lower risk of CAD, and clinical trials testing the inhibition of their protein products 
proved consistent with the genetic findings.13 
Here, we aimed at evaluating whether rare variants leading to decreased FX levels 
are associated with a lower risk of ischemic heart disease. We were able to show, for 
the first time, that rare damaging variants in the F10 gene are associated with 
reduced MI risk, thus providing a genetic support to the working hypothesis of clinical 
trials showing that FX inhibition may be beneficial for the treatment of ischemic heart 
disease. 
 
The study was conducted on an Italian cohort collected by “The Atherosclerosis, 
Thrombosis, and Vascular Biology Italian Study Group” (ATVB). The cohort is 
composed of 2,008 patients with early-onset MI (first event before 45 years) and an 
equal number of controls, matched for sex, age, and geographical origin. The clinical 
characteristics of the population are shown in Supplementary Table 1. 
Whole-exome sequencing was performed on the ATVB cohort at the Broad Institute 
(Boston, MA). Exome capture, sequencing, and data processing were previously 
described.14 Overall, sequencing of the FX gene (F10) was successful for 1,791 
cases and 1,750 controls. No null variants (nonsense, frameshift, splicing) were 
present in the cohort, in line with the constraint score reported in GnomAD repository 
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(https://gnomad.broadinstitute.org/), i.e. the ratio of the observed/expected (o/e) 
number of loss-of-function (LoF) variants in the gene (o/e=0.6, 90%CI=0.38-0.97), 
which indicates a certain degree of LoF mutation intolerance for F10. Conversely, 34 
different rare missense (listed in Supplementary Table 2) and 20 low-frequency 
synonymous variants were identified. A total of 86 subjects carried one missense 
variant in the heterozygous state, including 32 MI cases (1.8%), and 54 controls 
(3.1%). 
The 34 missense variants were analyzed using 5 algorithms, with the aim of 
predicting their damaging effect (for details, see Supplementary Materials). Only 5 
were predicted as damaging by all software (Supplementary Table 2). In parallel, we 
searched these 34 missense variants in publicly-available databases, finding that 
that 5 variations (p.E54G, p.G134R, p.E142K, p.G192R, p.G420R) were already 
described in patients affected by FX deficiency (Supplementary Table 2). 
Interestingly, only 3 of these (p.E54G, p.G134R, p.G420R) were predicted as 
damaging by all algorithms, whereas the variants p.E142K and p.G192R were 
recognized as pathogenic only by 3 and 1 software, respectively. 
We therefore performed an initial analysis including all variants identified as 
disruptive by all the 5 algorithms, plus those previously annotated as pathogenic in 
FX deficiency. When restricting the analysis to this set, we observed an enrichment 
in the burden of potentially deleterious variants among controls: in fact, 1.48% of 
controls carried at least one such rare mutation compared to only 0.78% of cases, 
(P=0.046, OR=0.51, 95%CI=0.26-0.99) (Figure 2A). This result highlighted a 
reduced risk of MI in subjects carrying a F10 deleterious mutation. When considering 
a broader set of variants (all the identified missense), we still observed a significant 
enrichment in controls (P=0.013, OR=0.57, 95%CI=0.36-0.89); as expected, when 
we analyzed all synonymous variants, no significant difference was detected in the 
distribution of variants between cases and controls (P=0.711, OR=1.08, 
95%CI=0.71-1.67). 
To corroborate our results, we tried to re-contact all carriers of the novel-identified 
mutations predicted to be damaging by the 5 algorithms to obtain a fresh blood 
sample for measuring FX antigen (FX:Ag) level and activity (FX:C). The evaluation 
was possible for 4 out of 5 variants, due to unavailability of the subject carrying the 
p.D73E variant. The results confirmed that all mutations diminish FX:C and FX:Ag 
levels when compared to healthy subjects (Figure 2B), highlighting a mild 
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disproportion between FX:Ag and FX:C. When compared with the mutation pattern 
detected in patients with FX deficiency,15 our findings suggest the hypothesis of an 
enrichment of “moderate-mild” missense changes with residual procoagulant 
function. The distribution of the mutated residues on the FXa structure is presented 
in Figure 2C. 
To confirm the enrichment of F10 variants among controls, we decided to focus on 
p.E142K, which was the most frequent among the deleterious variants 
(Supplementary Table 2). Indeed, in the ATVB cohort, we found a total of 35 carriers, 
corresponding to 0.72% of cases vs 1.26% of controls (P=0.127, OR=0.57, 
95%CI=0.26-1.2; Figure 3A). We hence genotyped by high-resolution melting 
analysis the p.E142K variant (for details, see Supplementary Methods) in an Italian 
replication cohort. This comprised 1,113 patients with angiographically documented 
CAD and 457 healthy controls (CAD-free), without any angiographic evidence of 
atherosclerosis, collected by the Verona Heart Study (VHS). The clinical 
characteristics of this population are shown in Supplementary Table 3. In the VHS, 
we identified a significantly higher proportion of heterozygous subjects in the CAD-
free group compared to cases (1.54% vs 0.27%, P=0.009, OR=0.18, 95%CI=0.03-
0.78) (Figure 3A). A meta-analysis of the 2 cohorts clearly highlighted a protective 
effect of the p.E142K allele (P=0.010, OR=0.45, 95%CI=0.24-0.88) (Figure 3A,B). 
The striking 6-fold increase in the p.E142K frequency observed among 
angiographically-documented CAD-free subjects suggests the intriguing hypothesis 
that this variant might impact primarily on FXa functions related to atherogenesis, 
rather than on those related to thrombosis. Indeed, apart from liver, FX is also 
produced locally by VSMCs, ECs, and inflammatory cells in atherosclerotic 
plaques;11 FXa stimulation is able to initiate senescence in VSMCs/ECs, and to 
induce the production of inflammatory cytokines, which impairs tissue regeneration 
by PAR-1 and PAR-2 signaling. By blocking FXa-mediated activation of these 
receptors, cell senescence and the production of inflammatory mediators are 
inhibited.16 
Of course, we have to acknowledge the limits of our work, which is an exploratory 
study based on a total of “only” 5,100 individuals, and should be hence further 
replicated in independent cohorts. Unfortunately, we were not able to confirm our 
results by digging publicly available MI/CAD datasets (i.e., 
http://www.cardiogramplusc4d.org/data-downloads). Here, data are given on 
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“aggregate” phenotypes and focused on common rather than rare variants and, as 
such, signals on F10 are overall flat. Instead, in the light of our observations 
(especially in the older VHS cohort), association/burden studies should be performed 
considering large-effect rare variants on angiographically-documented CAD-free vs 
CAD individuals. 
In conclusion, we showed for the first time that rare variants lowering FX levels are 
associated with a reduced risk of MI/CAD, thus supporting the role for this 
coagulation factor in the development of atherosclerosis. The reduced frequency of 
F10 mutations in MI/CAD patients also reassures on the potential risk of using FXa 
inhibition in unknown carriers of mild FX deficiency. Our study further stresses the 
utility to exploit human genetic variations impacting on drug-target genes as a proxy 
of the effect of pharmacological inhibition of the gene product in a life-long 
“experiment of nature”. 
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LEGENDS TO FIGURES 
 
Figure 1. Role of FX/FXa in blood coagulation and atherothrombosis. 
A) The panels show a simplified overview of blood coagulation, which has been sub-
divided in initiation, propagation, amplification, and clot formation phases. Clotting 
factors are indicated using Roman numbers, with the corresponding active form 
specified by “a”. Pharmacological inhibitors specifically targeting FXa are also listed. 
vWF, von Willebrand factor; TF, tissue factor. 
B) The figure shows a schematic representation of an artery, highlighting the 
different stages of the atherothrombotic process (from left to right). 
C) The scheme shows in more details the processes characterizing endothelial cell 
activation up to plaque rupture in atherothrombosis. Thrombin (IIa) and FXa play a 
fundamental role through the interactions with PARs (protease-activated receptors). 
The figure was created using BioRender (https://biorender.com/). 
 
Figure 2. Rare variants lowering the levels of coagulation FX are protective 
against early-onset MI. 
This study was approved by the Institutional Ethical Committees of the participating 
hospitals. All study participants signed an informed consent and gave information 
about their clinical history, and cardiovascular risk factors. 
A) Association of the burden of rare mutations in the F10 gene with the risk for early-
onset MI. Summary allele counts and carrier frequencies are shown (calculation 
performed on 1,791 cases and 1,750 controls); only variants with minor allele 
frequency less than 1% were considered in the burden analysis. The “deleterious” 
set is defined by missense variations predicted to be possibly damaging by all the 5 
algorithms used (LRT score, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 
HumVar, and SIFT) and those annotated as responsible for FX deficiency in publicly 
available databases. The “non-synonymous” set comprises all the missense 
variants; the “synonymous” set comprises the synonymous variants. All the tests 
were run using EPACTS. 
T1: alleles carrying variants with minor allele frequency less than 1%; Freq (%): 
percentage of cases or controls carrying a T1 allele; OR: odds ratio; CI: confidence 
interval. 
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B) FX coagulant activity (FX:C; light grey bars) and antigen levels (FX:Ag; dark grey 
bars) were measured in plasma of subjects carrying the newly identified missense 
variants (predicted to be damaging by all prediction programs). All analyzed subjects 
were not taking any anticoagulant drugs at time of the blood drawn. The normal 
range for FX:C is between 66% and 126%, and is represented by a light grey box 
delimited by dashed lines in the graph. The normal range for FX:Ag is between 70% 
and 150% (represented by solid lines). The protein variations are referred to the 
transcript NM_000504.3. Details on FX:C and FX:Ag measurements are specified in 
Supplementary Methods. 
C) Ribbon diagrams of secondary/tertiary structures of the human FXa are shown. 
The positions of 3 out of 4 newly identified missense mutations are reported (the 
region harboring the p.E54G variant is not included in the FXa structure). The 
position of the “frequent” p.E142K variant is also shown. The color code indicates the 
different FXa chains (shades of blue and green point to the light and heavy chains, 
respectively). The protein surface is represented to show that 3 out of four mutated 
residues are exposed to the solvent. Diagrams were produced using the UCSF 
Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics (http://www.rbvi.ucsf.edu/) software and the Protein Data Bank 1ezq 
entry. Image credits: Dr. Sonia Caccia (University of Milan; sonia.caccia@unimi.it). 
 
Figure 3. The F10 p.E142K (rs61753266) variant is protective against MI/CAD. 
A) Association analysis. The association between the presence of the p.E142K 
variant and MI/CAD status (Fisher’s exact test) was tested in 2 Italian cohorts (ATVB 
and VHS). Summary allele counts and carrier frequencies are shown. T1: alleles 
carrying the p.E142K variant; Freq (%): percentage of cases or controls carrying a 
T1 allele; OR: odds ratio; CI: confidence interval. 
B) Meta-analysis. The meta-analysis was performed using the Mantel-Haenszel 
fixed-effects model, as already described for rare variants (see Supplementary 
Materials). The squares indicate the estimated OR for carriers, as compared with 
non-carriers, in each group. The diamond indicates the combined results. 
For all analyses, a P<0.05 was considered statistically significant; calculations were 
performed using the R software (https://www.r-project.org/). 
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SUPPLEMENTARY METHODS 
 
Definition of disrupting variants and statistical analysis 
We searched the FX gene (F10) for deleterious variants (nonsense, frameshift, splicing, or 
disrupting missense mutations). To define as deleterious all those missense variants that 
could potentially impair FX protein function, we used both a bioinformatics and a data-
mining approach. Rare missense variants were considered damaging if: a) they were 
predicted to be deleterious or possibly deleterious by all the 5 prediction algorithms used: 
LRT (likelihood ratio test),1 MutationTaster,2 PolyPhen-2 HumDiv, PolyPhen-2 HumVar,3 
and SIFT;4 and/or b) were annotated as responsible for FX deficiency (OMIM #227600) in 
publicly available databases (ClinVar,5 FX deficiency database 
[https://www.isth.org/?MutationsRareBleedin]). 
We performed the analyses on different sets of variants: 1) deleterious variants, defined by 
a combination of in-silico and data-mining analysis, as just described; 2) all non-
synonymous variants; 3) all synonymous variants, as a negative control. 
The positions of variants were based on the cDNA reference sequence for F10 
(NM_000504.3) with the ATG initiation codon numbered as residue 1 (p.Met1). 
All the analyses were performed considering only those variants having a minor allele 
frequency (MAF) <1%, and were carried out using the EPACTS software 
(http://genome.sph.umich.edu/wiki/EPACTS), the “b.collapse” option (logistic Wald Test 
between binary phenotypes and collapsed variables), and correcting for the first 5 principal 
components of ancestry. 
The meta-analysis was performed using the Mantel-Haenszel fixed-effects model, as 
already described for rare variants, as detailed in.6 
A P<0.05 was considered to indicate statistical significance. 
 
Evaluation of FX antigen level and activity on plasma of selected subjects 
The FX coagulant activity (FX:C) was measured with a one-stage prothrombin time (PT) 
assay performed on an ACL3000 automated analyzer (Instrumentation Laboratory, Milan, 
Italy). The FX:C values were calculated using, as a reference, plasma pooled from 40 
healthy subjects (20 men, and 20 women who were not pregnant and were not taking oral 
contraceptives). The reference plasma was assigned an arbitrary FX:C value of 100%. 
FX antigen levels (FX:Ag) were measured using an in-house enzyme immunoassay. 
Microtitre plates were coated overnight at room temperature with rabbit anti-human FX 
polyclonal antibody (Dako, Ely, UK) diluted 1:800. A standard curve was produced using 
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serial dilutions of pooled normal plasma. Samples were incubated for 2h at room 
temperature. Plates were washed and incubated again with a 1:650 dilution of horseradish 
peroxidase conjugated rabbit anti-human FX polyclonal antibody used in the coating step 
for 2h at room temperature. The enzymatic activity was detected by ortho-phenylene-
diamine; the reaction was stopped with a solution of H2SO4 and optical density was 
determined at 492nm. FX:Ag levels were calculated using as a reference the same pooled 
plasma used for the FX:C assay. 
 
Genotyping of the rs61753266 (p.E142K) variant 
The rs61753266 (p.E142K) variant was genotyped in the Verona Hearth Study (VHS) 
cohort by high-resolution melting (HRM) analysis, using the LightCycler 480 (Roche, 
Indianapolis, USA) and the Precision Melt Supermix (Biorad, Hercules, United States), 
following the manufacturer’s instructions. Amplicons were analyzed with the Gene 
Scanning Software (Roche). All samples identified as heterozygous by HRM analysis were 
further confirmed by direct sequencing using the BigDye Terminator Cycle Sequencing 
Ready Reaction Kit v1.1 (Thermo Fisher Scientific, Waltham, USA), and the ABI-3500 
Genetic Analyzer (Thermo Fisher Scientific). 
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Supplementary Table 1. Clinical characteristics of the ATVB population. 
 
Characteristics 
Cases (n=1,791) Controls 
(n=1,750) 
P 
Age (years)* 39.5  4.9 39.6  4.9  
Male sex (%) 89.4 86.8  
Diabetes (%) 5.5 0.5 <0.001† 
Hypercholesterolemia 
(%) 
60.5 48.7 <0.001‡ 
Hypertension (%) 27.1 9.1 <0.001‡ 
BMI >25 (%) 62.8 42 <0.001‡ 
Current smokers (%) 45.1 30.2 <0.001‡ 
 
* Data are shown as mean ± standard deviation. Age at onset for cases. 
† Continuous data were tested using 2-tailed Student t test. 
‡ Categorical data were tested using a χ2 test. 
Subjects were considered to have diabetes if they were reported to have type I or II 
diabetes; hypertension was defined as diastolic blood pressure ≥90mmHg, or systolic 
blood pressure ≥140mmHg or current use of antihypertensive medication; 
hypercholesterolemia was defined by total cholesterol concentration 200 mg/dL or 
ongoing statin therapy. 
BMI: body mass index. 
Details about enrollment criteria were described elsewhere.7,8 
Statistical analyses were performed using the using the R software (https://www.r-
project.org/). 
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Supplementary Table 2. List of all rare missense variants identified in the F10 gene 
in the ATVB cohort. 
 
Position (hg19)* 
dbSNP 
identifier 
Protein 
variation† 
N cases/ 
N controls 
Literature‡ 
Bioinformatics 
prediction§ 
13:113777177_G/A n.a. p.R3H 0/1 
 
0/5 
13:113777234_A/G rs778995263 p.E22G 1/0 
 
0/5 
13:113783785_G/C rs5961 p.Q30H 1/2 
 
0/5 
13:113783838_T/C rs750510185 p.M48T 1/0 
 
2/5 
13:113783856_A/G rs121964944 p.E54G 0/1 9,10 5/5 
13:113783914_C/G rs766511333 p.D73E 0/1 
 
5/5 
13:113792784_A/G rs764589800 p.N82S 1/0 
 
1/5 
13:113793676_G/A rs767111216 p.D88N 1/0 
 
3/5 
13:113793724_G/A rs778616029 p.G104S 1/1 
 
4/5 
13:113795244_C/T rs763662689 p.L128F 1/0 
 
0/5 
13:113795262_G/A rs368225671 p.G134R 0/1 10,11 5/5 
13:113795286_G/A rs61753266 p.E142K 13/22 10,12 3/5 
13:113795316_G/A rs3211772 p.A152T 0/1 
 
4/5 
13:113795320_G/A rs370999670 p.R153H 1/3 
 
0/5 
13:113795338_A/G rs776162435 p.D159G 0/1 
 
3/5 
13:113795343_G/A rs375847622 p.G161S 0/1 
 
2/5 
13:113798212_G/C rs148472205 p.V184L 0/2 
 
0/5 
13:113798236_G/A rs3211783 p.G192R 0/2 10
||
 1/5 
13:113798266_C/T rs772057533 p.P202S 1/0 
 
1/5 
13:113798272_G/A rs775409712 p.D204N 1/0 
 
0/5 
13:113798281_G/A rs753682438 p.D207N 1/0 
 
0/5 
13:113798308_G/A rs144711550 p.D216N 2/3 
 
0/5 
13:113798330_C/T rs566300775 p.T223M 0/1 
 
3/5 
13:113798393_G/A rs761589067 p.G244E 0/1 
 
5/5 
13:113803236_G/A rs149212700 p.R291Q 3/3 
 
3/5 
13:113803266_C/T rs145282353 p.A301V 0/1 
 
1/5 
13:113803311_A/G rs144679674 p.K316R 1/0 
 
1/5 
13:113803336_C/T rs747057515 p.P321L
#
 0/1 
 
2/5 
13:113803337_G/A rs373791924 p.V325M 1/0 
 
3/5 
13:113803380_C/T rs201675411 p.A339V 0/1 
 
1/5 
13:113803461_G/A rs143715673 p.R366H 0/1 
 
3/5 
13:113803622_G/A rs750759634 p.G420R 1/0 13,14 5/5 
13:113803673_G/A rs776671034 p.V437I 0/1 
 
2/5 
13:113803772_G/A rs200826349 p.G470S 0/2 
 
1/5 
Variants predicted to be deleterious by 5 out of 5 algorithms are bolded. 
* Position is according to the human genome release GRCh37/hg19, February 2009; 
† Protein variation is referred to the transcript NM_000504.3; 
‡ Retrieved from: FX deficiency database [https://www.isth.org/?MutationsRareBleedin]), 
ClinVar; 
  6 
§ Prediction performed with: LRT, MutationTaster, PolyPhen-2 HumDiv, PolyPhen-2 
HumVar, and SIFT; 
|| Found in the double homozygous state with Ala274Ser; 
# Protein variation is referred to the transcript NM_001312675.1; 
n.a. not annotated in dbSNP146. 
  
  7 
Supplementary Table 3. Clinical characteristics of the VHS population. 
 
Characteristics 
CAD-Free 
(n=454) 
CAD (n=1105) P 
Age (years)* 59.5±12.5 61.3±10.0 0.006† 
Male sex (%) 63.7 79.8 <0.001‡ 
BMI (kg/m2) 25.2±4.5 26.4±4.7 <0.001† 
Hypertension (%) 44.0 65.9 <0.001‡ 
Smoking (%)§ 42.9 68.6 <0.001‡ 
Diabetes (%) 9.2 19.5 <0.001‡ 
Hypercholesterolemia (%)∥ 58.9 70.7 <0.001
‡ 
 
Data are presented as mean ± standard deviation or %. Only data concerning 
angiographically examined individuals are shown. 
* Age at onset for cases and age at examination for controls. 
† Continuous data were tested using 2-tailed Student t test. 
‡ Categorical data were tested using a χ2 test. 
§ Current and former smokers were aggregated in the single category of smokers. 
∥ Hypercholesterolemia was defined by total cholesterol concentration >5.2 mmol/L or 
presence of lipid-lowering therapy. 
Details about enrollment criteria were described elsewhere.15,16 
Statistical analyses were performed using the using the R. 
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